HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2003.014985v1 64/4/564    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolf, J Articles by Smolen, J S Search for Related Content PubMed PubMed Citation Articles by Wolf, J Articles by Smolen, J S

Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis

¹ Second Department of Medicine, Lainz Hospital, Vienna, Austria
² Department of Internal Medicine I, University of Vienna

Correspondence to:
Correspondence to:
Professor Josef S Smolen
Second Department of Medicine, Lainz Hospital, Wolkersbergenstr 1, A-1130 Vienna, Austria; josef.smolen{at}wienkav.at

Background: Methotrexate is transported into the cell by the reduced folate carrier (RFC) and out of the cell by members of the multidrug resistance protein family (MRP). Transport proteins may affect the therapeutic efficacy of this drug in patients with rheumatoid arthritis.

Objective: To investigate the potential benefit of the presence of RFC and the absence of functional MRP for the efficacy of methotrexate treatment.

Methods: The study involved 163 patients (116 female, 47 male; mean age 59.5 years) on methotrexate (mean weekly dose 12.2 mg). RFC was determined using reverse transcriptase polymerase chain reaction, and MRP function by flow cytometry, using a calcein acetoxymethylesther/probenecid assay. Clinical response to methotrexate was evaluated by the EULAR response criteria and the ACR 20% improvement criteria. The clinical data were obtained at the beginning of methotrexate treatment and at the time of blood sampling during ongoing therapy. Patients were divided into four groups according to the presence (+) or absence (–) of RFC and functional (f) MRP.

Results: fMRP+/RFC+ and fMRP–/RFC– patients more often had good EULAR response rates (60%, p = 0.014, and 53%, p = 0.035, respectively) in comparison with the fMRP–/RFC+ group (29%); fMRP+/RFC– patients had a low frequency of good disease activity responses.

Conclusions: Absence of fMRP plus presence of RFC did not prove to be related to beneficial effects of methotrexate, but the lack or the presence of both fMRP and RFC led to a significantly better therapeutic outcome. Determination of these markers may predict responsiveness to methotrexate.

Abbreviations: ACR, American College of Rheumatology; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; EULAR, European League Against Rheumatism; fMRP, functional multidrug resistance proteins; FPGS, folylpolyglutamyl synthetase; MRP, multidrug resistance protein family; NSAID, non-steroidal anti-inflammatory drug; RFC, reduced folate carrier; VAS, visual analogue scale

Keywords: methotrexate; multidrug resistance proteins; reduced folate carrier; rheumatoid arthritis

This article has been cited by other articles:

				B. Baslund, J. Gregers, and C. H. Nielsen Reduced folate carrier polymorphism determines methotrexate uptake by B cells and CD4+ T cells Rheumatology, April 1, 2008; 47(4): 451 - 453. [Abstract] [Full Text] [PDF]

				S L Hider, A Owen, R Hartkoorn, S Khoo, D Back, A J Silman, and I N Bruce Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug Ann Rheum Dis, October 1, 2006; 65(10): 1390 - 1393. [Abstract] [Full Text] [PDF]